Overview

CMC systems and processes play a pivotal role in the development, licensure, manufacture, and ongoing marketing of biopharmaceutical and device products that are consistently effective, safe, and high quality for patients.

DIA's CMC Workshop will provide a thorough understanding of the regulatory, technical, and quality requirements and strategies needed to support problem-solving as well as continuous improvements and innovation in biopharmaceutical manufacturing. Opportunities for interactive sharing of information and approaches will be an important part of the program.

This program has been developed in collaboration with the DIA CMC Working Group and Regulatory Affairs Community.

CMC Resource Guide

What's going on in CMC? Check out our Resource Guide for the latest news in the field including reoccurring challenges and possible solutions, as well as informative articles and exclusive podcast interviews. Also gain more insight into the CMC Workshop and what hot topics will be discussed.

DOWNLOAD GUIDE

On-Demand Content Preview Webinar

Can I Implement That Now? Efficiently Managing Post-Approval CMC Changes.
Listen in on a recording from the DIA 2018 Global Annual Meeting, with a Q&A at the end with experts Peter Lassoff, PharmD, FTOPRA, and Mark Wiggins, MS.
Register today.

Featured

Want to learn more about CMC Workshop ? You've come to the right site!

Who should attend?

Professionals involved in:

CMC Regulatory Affairs
CMC Writing
Quality Assurance/Quality Control
Regulatory Compliance
API Development and Manufacturing
Formulation Development and Manufacturing
Analytical Development
CMC Lifecycle Management
CMC Project Management

Learning objectives

At the conclusion of this workshop, participants should be able to:

Discuss the current CMC topics for chemical and biological products in a globalized environment
Explain challenges and opportunities for CMC and GMP in accelerated drug development
Discuss the impact of emerging technologies in drug development
Describe recent ICHQ2 and ICHQ14 updates
Discuss concepts of the patient centric Quality Overall Summary (QOS) as advanced by FDA
Discuss challenges in the development and manufacture of complex drug delivery devices
Outline the current general process for complex generics approval
Describe CMC regulatory updates in international markets
Explain the concepts and elements of process monitoring for CMC

Program Committee

LeeAnn L Chambers, MS Principal Research Scientist, Global Regulatory Affairs, CMC - Devices
Eli Lilly and Company, United States
Andrew Chang, PhD Vice President, Quality and Regulatory Compliance
Novo Nordisk, United States
Cheryl Emery Associate VP, GRACS and Global Head CMC Pre-Approval Pharmaceuticals
Merck Research Laboratories, United States
M. Scott Furness, PhD Deputy Director, Office of New Drug Products, OPQ, CDER
FDA, United States
Annie W Sturgess, PhD Vice President, Global Regulatory Sciences, CMC
Bristol-Myers Squibb Company, United States